Maximum likelihood estimation of renal transporter ontogeny profiles for pediatric PBPK modeling
CPT: Pharmacometrics & Systems Pharmacology · 2024-04 · 13 (4) · 576-588
DOI: 10.1002/psp4.13102 ↗Kurz gefasst
Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 10.01.2024. Verfasst von J Porter Hunt und 8 weiteren Autor:innen. Beteiligte Einrichtung: University of Utah, Salt Lake City, Utah, USA. Hauptthemen laut MEDLINE: Furosemide, Neoplasm Proteins. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDDK NIH HHS, NICHD NIH HHS.
Abstract (Originalsprache)
Optimal treatment of infants with many renally cleared drugs must account for maturational differences in renal transporter (RT) activity. Pediatric physiologically‐based pharmacokinetic (PBPK) models may incorporate RT activity, but this requires ontogeny profiles for RT activity in children, especially neonates, to predict drug disposition. Therefore, RT expression measurements from human kidney postmortem cortical tissue samples were normalized to represent a fraction of mature RT activity. Using these data, maximum likelihood estimated the distributions of RT activity across the pediatric age spectrum, including preterm and term neonates. PBPK models of four RT substrates (acyclovir, ciprofloxacin, furosemide, and meropenem) were evaluated with and without ontogeny profiles using average fold error (AFE), absolute average fold error (AAFE), and proportion of observations within the 5–95% prediction interval. Novel maximum likelihood profiles estimated ontogeny distributions for the following RT: OAT1, OAT3, OCT2, P‐gp, URAT1, BCRP, MATE1, MRP2, MRP4, and MATE‐2 K. Profiles for OAT3, P‐gp, and MATE1 improved infant furosemide and neonate meropenem PBPK model AFE from 0.08 to 0.70 and 0.53 to 1.34 and model AAFE from 12.08 to 1.44 and 2.09 to 1.36, respectively, and improved the percent of data within the 5–95% prediction interval from 48% to 98% for neonatal ciprofloxacin simulations, respectively. Even after accounting for other critical population‐specific maturational differences, novel RT ontogeny profiles substantially improved neonatal PBPK model performance, providing validated estimates of maturational differences in RT activity for optimal dosing in children.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Utah, Salt Lake City, Utah, USA.
- University of Waterloo, Waterloo, Ontario, Canada.
- Genentech, Inc., South San Francisco, California, USA.
- Roche Pharma and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland.
- UCSF, San Francisco, California, USA.
- Erasmus MC, Rotterdam, The Netherlands.
Förderung
- NIDDK NIH HHS
- NICHD NIH HHS
Zitieren
APA
Hunt, J. P., Dubinsky, S., McKnite, A. M., Cheung, K. W. K., van Groen, B. D., Giacomini, K. M., de Wildt, S. N., Edginton, A. N., & Watt, K. M. (2024). Maximum likelihood estimation of renal transporter ontogeny profiles for pediatric PBPK modeling. CPT: Pharmacometrics & Systems Pharmacology, 13(4), 576-588. https://doi.org/10.1002/psp4.13102
Vancouver
Hunt JP, Dubinsky S, McKnite AM, Cheung KWK, van Groen BD, Giacomini KM, et al. Maximum likelihood estimation of renal transporter ontogeny profiles for pediatric PBPK modeling. CPT: Pharmacometrics & Systems Pharmacology. 2024;13(4):576-588. doi:10.1002/psp4.13102
BibTeX
@article{Hunt2024,
author = {Hunt, J Porter and Dubinsky, Samuel and McKnite, Autumn M and Cheung, Kit Wun Kathy and van Groen, Bianca D and Giacomini, Kathleen M and de Wildt, Saskia N and Edginton, Andrea N and Watt, Kevin M},
title = {Maximum likelihood estimation of renal transporter ontogeny profiles for pediatric PBPK modeling},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2024},
volume = {13},
number = {4},
pages = {576--588},
doi = {10.1002/psp4.13102}
}
EUVIMED